表紙
市場調査レポート

季節性アレルギー性鼻炎のパイプライン分析

Seasonal Allergic Rhinitis - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 245991
出版日 ページ情報 英文 49 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.39円で換算しております。
Back to Top
季節性アレルギー性鼻炎のパイプライン分析 Seasonal Allergic Rhinitis - Pipeline Review, H1 2016
出版日: 2016年03月16日 ページ情報: 英文 49 Pages
概要

季節性アレルギー性鼻炎(花粉症)とは、大気に運ばれてくる花粉により発症する疾患です。主な症状として、鼻・口蓋・喉・目のかゆみや、鼻水・鼻づまり、催涙、目の下の隈などが挙げられます。疾病素質には年齢や家族歴、他のアレルギー症状の存在などがあります。主な治療薬にはコルチコステロイドや抗ヒスタミン剤、充血緩和剤(鼻づまり薬)などが含まれています。

当レポートでは、世界各国での季節性アレルギー性鼻炎治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

季節性アレルギー性鼻炎の概要

治療薬の開発

  • 季節性アレルギー性鼻炎向けパイプライン製品:概要
  • 季節性アレルギー性鼻炎向けパイプライン製品:比較分析

各企業で開発中の季節性アレルギー性鼻炎治療薬

大学/研究機関で研究中の季節性アレルギー性鼻炎治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品

季節性アレルギー性鼻炎治療薬:開発中の製品の一覧(企業別)

季節性アレルギー性鼻炎治療薬:研究中の製品の一覧(大学/研究機関別)

季節性アレルギー性鼻炎治療薬の開発に従事している企業

  • Adamis Pharmaceuticals Corporation
  • FAES Farma SA
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd.
  • Merck & Co., Inc.
  • 田辺三菱製薬
  • 小野薬品工業
  • 塩野義製薬
  • VentiRx Pharmaceuticals, Inc.

季節性アレルギー性鼻炎:治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • (azelastine hydrochloride + mometasone furoate)
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • APC-3000
  • bepotastine besylate
  • bilastine
  • desloratadine
  • GSP-301
  • levocabastine hydrochloride
  • ONO-4053
  • S-555739
  • VTX-1463
  • ■季節性アレルギー性鼻炎治療薬:パイプライン製品の最新動向

季節性アレルギー性鼻炎治療薬:開発が休止状態の製品

季節性アレルギー性鼻炎治療薬:開発が中止された製品

季節性アレルギー性鼻炎関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7768IDB

Summary

Global Markets Direct's, 'Seasonal Allergic Rhinitis - Pipeline Review, H1 2016', provides an overview of the Seasonal Allergic Rhinitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Seasonal Allergic Rhinitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Seasonal Allergic Rhinitis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Seasonal Allergic Rhinitis
  • The report reviews pipeline therapeutics for Seasonal Allergic Rhinitis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Seasonal Allergic Rhinitis therapeutics and enlists all their major and minor projects
  • The report assesses Seasonal Allergic Rhinitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Seasonal Allergic Rhinitis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Seasonal Allergic Rhinitis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Seasonal Allergic Rhinitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Seasonal Allergic Rhinitis Overview
  • Therapeutics Development
    • Pipeline Products for Seasonal Allergic Rhinitis - Overview
  • Seasonal Allergic Rhinitis - Therapeutics under Development by Companies
  • Seasonal Allergic Rhinitis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
  • Seasonal Allergic Rhinitis - Products under Development by Companies
  • Seasonal Allergic Rhinitis - Companies Involved in Therapeutics Development
    • Adamis Pharmaceuticals Corporation
    • Faes Farma, SA
    • Glenmark Pharmaceuticals Ltd.
    • Hisamitsu Pharmaceutical Co., Inc.
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Shionogi & Co., Ltd.
    • VentiRx Pharmaceuticals, Inc.
  • Seasonal Allergic Rhinitis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • APC-3000 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • asapiprant - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bilastine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • desloratadine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • emedastine difumarate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GSP-301 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PF-06444752 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PF-06444753 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VTX-1463 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Seasonal Allergic Rhinitis - Recent Pipeline Updates
  • Seasonal Allergic Rhinitis - Dormant Projects
  • Seasonal Allergic Rhinitis - Discontinued Products
  • Seasonal Allergic Rhinitis - Product Development Milestones
    • Featured News & Press Releases
      • Oct 11, 2013: FDA Approves Sanofi's Nasacort Allergy 24HR for Over-the-Counter Use
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Seasonal Allergic Rhinitis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Seasonal Allergic Rhinitis - Pipeline by Adamis Pharmaceuticals Corporation, H1 2016
  • Seasonal Allergic Rhinitis - Pipeline by Faes Farma, SA, H1 2016
  • Seasonal Allergic Rhinitis - Pipeline by Glenmark Pharmaceuticals Ltd., H1 2016
  • Seasonal Allergic Rhinitis - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H1 2016
  • Seasonal Allergic Rhinitis - Pipeline by Merck & Co., Inc., H1 2016
  • Seasonal Allergic Rhinitis - Pipeline by Pfizer Inc., H1 2016
  • Seasonal Allergic Rhinitis - Pipeline by Shionogi & Co., Ltd., H1 2016
  • Seasonal Allergic Rhinitis - Pipeline by VentiRx Pharmaceuticals, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Seasonal Allergic Rhinitis Therapeutics - Recent Pipeline Updates, H1 2016
  • Seasonal Allergic Rhinitis - Dormant Projects, H1 2016
  • Seasonal Allergic Rhinitis - Dormant Projects (Contd..1), H1 2016
  • Seasonal Allergic Rhinitis - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Seasonal Allergic Rhinitis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top